| Drug Name |
Lumateperone |
| Drug ID |
BADD_D02565 |
| Description |
Schizophrenia is a complex mental illness and impacts approximately 1% of the population.[L10902] Although there are several antipsychotics including [aripiprazole], [paliperidone] and [clozapine] available for clinical use, they are generally accompanied by significant metabolic and/or neurological adverse effects.[A189093]
Lumateperone is a newly approved 2nd generation antipsychotic currently indicated for the treatment of schizophrenia.[A189093] It has a unique receptor binding profile and differs from other antipsychotics in that it modulates glutamate, serotonin and dopamine, which are all neurotransmitters that contribute to the pathophysiology of schizophrenia.[A189093,A189174]
The data so far indicates that lumateperone can alleviate both positive and negative symptoms of schizophrenia.[A189093] Further, not only is the new antipsychotic selective for dopamine (D2) receptors in the mesolimbic and mesocortical brain regions, but it also has minimal off-target activity.[A189093] Both characteristics lend to a more favourable adverse effect profile and ultimately safer drug.[A189093,L10908] |
| Indications and Usage |
Lumateperone is approved for the treatment of schizophrenia in adults.[L10860] |
| Marketing Status |
approved; investigational |
| ATC Code |
N05AD10 |
| DrugBank ID |
DB06077
|
| KEGG ID |
D11169
|
| MeSH ID |
C000705749
|
| PubChem ID |
21302490
|
| TTD Drug ID |
D1CWL0
|
| NDC Product Code |
72060-142; 72060-110; 70518-3497; 66406-0300; 72060-121 |
| UNII |
70BSQ12069
|
| Synonyms |
lumateperone | ITI-007 | ITI-722 | lumateperone tosylate |
